Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The prognostic impact of minimal disseminated disease (MDD) and anti-anaplastic lymphoma kinase (ALK) antibody titer in children with ALK-positive anaplastic large cell lymphoma (ALCL) was reported by an Italian/German group. Here, we examine their prognostic value in Japanese children with ALK-positive ALCL. We evaluated nucleophosmin (NPM)-ALK transcripts in 60 patients at diagnosis by RT-PCR and real-time PCR (qPCR). The antibody titer was assessed in 35 patients. Fifty-two percent were MDD positive by RT-PCR and 37% had more than 10 copies of NPM-ALK per 10 copies of ABL (10NCNs) by qPCR. Fifty-one percent of 35 patients had high antibody titer (> 1/750). Progression-free survival (PFS) of the patients with > 10 NCNs or low antibody titers was significantly poorer than that of patients with ≤ 10 NCNs or high antibody titers (> 1/750) (P = 0.016, 0.029), respectively, although we observed no difference in PFS associated with positive MDD on RT-PCR. On stratification using a combination of MDD and antibody titer, PFS for patients with > 10 NCNs and low antibody titer was extremely low (30.0%). Combined evaluation of MDD and anti-ALK antibody titer at diagnosis may thus be valuable for stratification of treatment for childhood ALCL.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12185-017-2338-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Inhibitor development and clinical characteristics in children with severe hemophilia A in the ATHN 8 US cohort study.
Blood Vessel Thromb Hemost
August 2025
Divsion of Hematology, Oncology & Bone Marrow Transplantation, Department of Pediatrics, Children's Mercy Hospital, Kansas City, MO.
Clotting factor concentrate (CFC), used to treat and prevent bleeding in hemophilia, is rendered ineffective if clotting factor neutralizing antibodies (inhibitors) develop. Inhibitors occur most often in children, early in treatment. The American Thrombosis and Hemostasis Network (ATHN) 8: US Cohort Study of Previously Untreated Patients (PUPs) with Congenital Hemophilia, conducted in children born in 2010 to 2020 with severe or moderate hemophilia, was designed to determine the percentage of participants who developed a confirmed, clinically significant inhibitor within the first 50 CFC exposure days (EDs).
View Article and Find Full Text PDFDistinct effects of adjuvants on B cell responses to protein or polysaccharide antigens contained in glycoconjugate vaccines.
Front Immunol
September 2025
Bacterial Scientific Area, GSK Vaccine, Siena, Italy.
Background: Protein-polysaccharide conjugate vaccines rely on the induction of T-cell-dependent responses that support germinal center (GC) reactions to potentiate the expansion of antigen-specific memory B-cell (MBC) populations and high-avidity antibody responses. The effects of adjuvants on B-cell and antibody responses are well described for protein antigens but remain largely unexplored for conjugated polysaccharidic antigens.
Methods: We assessed the effects of five adjuvants present in licensed vaccines (AS01, AS03, AS04, and aluminum hydroxide [Alum]) or under clinical evaluation (AS37) on the magnitude and quality of antigen-specific antibody responses and local/systemic B-cell responses.
Prevalence and clinical implications of major and minor ANCAs in Tunisian (North African) patients with systemic lupus erythematosus.
Front Immunol
September 2025
Clinical Immunology Department, Pasteur Institute of Tunis, Tunis, Tunisia.
Introduction: Anti-neutrophil cytoplasmic antibodies (ANCAs) have been reported in systemic lupus erythematosus (SLE). Their clinical significance remains unclear especially in the African populations. This study aimed to assess the prevalence, antigenic targets, and clinical correlations of ANCAs in SLE patients in a Tunisian (North African) cohort.
View Article and Find Full Text PDFFalse positive results in the Widal test in adults immunized with the Commirnaty (Pfizer-BioNtech) and BBIBP-CorV (Sinopharm) vaccines against COVID-19.
Front Med (Lausanne)
August 2025
School of Medicine, Universidad Norbert Wiener, Lima, Peru.
Introduction: Vaccination against COVID-19 has generated a dramatic reduction in deaths and infections worldwide. However, there may be cross-reactivity with numerous biochemical and immunological markers. The Widal test for the detection of typhoid fever is an antigen-antibody test that can be affected by vaccination, causing errors in the results, so we determined the frequency of false positive results of the Widal test in adults vaccinated with Commirnaty (Pfizer -BioNtech) and BBIBP-CorV (Sinopharm) vaccines.
View Article and Find Full Text PDFCD19CD11cT-bet B cells in myasthenia gravis: a potential biomarker.
Front Neurol
August 2025
Department of Neurology, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, China.
Background: Myasthenia gravis (MG), an autoimmune disorder characterized by B cell-driven autoantibody production, exhibits heterogeneous B cell subsets dysregulation and incompletely defined signaling mechanisms.
Methods: A cohort of 20 naïve MG patients positive for anti-acetylcholine receptor (AChR) antibodies and 15 healthy controls was analyzed. Peripheral blood mononuclear cells underwent proteomic profiling, flow cytometry (age-associated B cells (ABCs), plasma cells, T follicular helper cells, and regulatory B cells), and western blot validation of nuclear factor kappa-B (NF-κB)/cellular reticuloendotheliosis oncogene homolog (c-Rel) expression.